Table 1.
Baseline Characteristics
| Overall | CVD event | No CVD event | P value* | |
|---|---|---|---|---|
| (N=9412) | (N=309) | (N=9103) | ||
| Demographics | ||||
| Age, y, median (quartile 1–quartile 3) | 45.1 (39.1–51.4) | 50.9 (45.3–57.1) | 45.0 (38.9–51.2) | <0.0001 |
| Male sex, n (%) | 8148 (86.6) | 272 (88.0) | 7876 (86.5) | 0.4454 |
| Other | 0.0166 | |||
| Black, n (%) | 1649 (17.5) | 62 (20.1) | 1587 (17.4) | |
| Hispanic, n (%) | 1586 (16.9) | 43 (13.9) | 1543 (17.0) | |
| White, n (%) | 4933 (52.4) | 176 (57.0) | 4757 (52.3) | |
| Other, n (%) | 857 (9.1) | 25 (8.1) | 832 (9.1) | |
| Unknown/missing, n (%) | 387 (4.1) | 3 (1.0) | 384 (4.2) | |
| Traditional CVD risk factors | ||||
| Hypertension, n (%) | 2219 (23.6) | 135 (43.7) | 2084 (22.9) | <0.0001 |
| Systolic blood pressure, median (quartile 1–quartile 3) | 122 (112–132) | 128 (116–139) | 122 (112–132) | <0.0001 |
| Diastolic blood pressure, median (quartile 1–quartile 3) | 76 (69–83) | 79 (71–87) | 76 (69–82) | <0.0001 |
| Hypertension treatment, n (%) | 2547 (27.1) | 140 (45.3) | 2407 (26.4) | <0.0001 |
| Hyperlipidemia, n (%) | 2984 (31.7) | 156 (50.5) | 2828 (31.1) | <0.0001 |
| Total cholesterol, median (quartile 1–quartile 3) | 179 (152–207) | 188 (152–220) | 179 (152–207) | 0.0037 |
| HDL cholesterol, median (quartile 1–quartile 3) | 42 (35–51) | 39 (33–48) | 42 (35–51) | <0.0001 |
| Statin treatment, n (%) | 1441 (15.3) | 92 (29.8) | 1349 (14.8) | <0.0001 |
| Diabetes mellitus, n (%) | 573 (6.1) | 42 (13.6) | 531 (5.8) | <0.0001 |
| Smoking, n (%) | 2461 (26.1) | 112 (36.2) | 2349 (25.8) | <0.0001 |
| CHD event, n (%) | 158 (1.7) | 158 (51.1) | 0 (0.0) | <0.0001 |
| HIV‐related factors | ||||
| CD4 count, median (quartile 1–quartile 3) | 492 (316–690) | 451 (268–665) | 495 (318–691) | 0.0146 |
| CD4 count nadir, median (quartile 1–quartile 3) | 283 (132–468) | 190 (64–344) | 286 (135–471) | <0.0001 |
| HIV RNA <400 (copies/mL), n (%) | 6356 (68.0) | 217 (71.1) | 6139 (67.9) | 0.2341 |
| Antiretroviral therapy, n (%) | 7833 (83.2) | 266 (86.1) | 7567 (83.1) | 0.1712 |
| NRTI, n (%)† | 7618 (97.3%) | 257 (96.6%) | 7361 (97.3%) | 0.5166 |
| NNRTI, n (%)† | 3871 (49.4%) | 95 (35.7%) | 3776 (49.9%) | <0.0001 |
| PI, n (%)† | 3281 (41.9) | 160 (60.2) | 3121 (41.2) | <0.0001 |
| INSTI, n (%)† | 1609 (20.5) | 40 (15.0) | 1569 (20.7) | 0.0238 |
| Other, n (%)† | 1450 (18.5) | 42 (15.8) | 1408 (18.6) | 0.2449 |
| Duration HIV, median (Q1, Q3) | 6.5 (1.3–14.1) | 9.7 (3.1–17.2) | 6.4 (1.3–14.0) | <0.0001 |
| Cohort characteristics | ||||
| Year of baseline, median (IQR) | 2009 (2006–2013) | 2008 (2005–2011) | 2009 (2006–2013) | <0.0001 |
| Follow‐up time, median (quartile 1–quartile 3) | 5.2 (2.4–10.0) | 4.3 (2.1–6.9) | 5.3 (2.4–10.0) | <0.0001 |
CHD indicates coronary heart disease; CVD, cardiovascular disease; HDL, high‐density lipoprotein; INSTI, integrase strand transfer inhibitor; IQR, interquartile range, NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; and PI, protease inhibitor.
*
Kruskal–Wallis test was used to generate P values for continuous variables, and χ2 test was used to generate P values for categorical variables. P values are for the comparison of individuals with a CVD event vs those with no CVD event.
†
Percent of those on antiretroviral therapy.